Research and Clinical Center for Yusho and Dioxin, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan.
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashiku, Fukuoka 812-8582, Japan.
Cell Death Dis. 2017 Jul 13;8(7):e2931. doi: 10.1038/cddis.2017.322.
Filaggrin (FLG) mutation is a well-confirmed genetic aberration in atopic dermatitis (AD). Genome-wide association studies on AD have revealed other susceptibility genes, for example, Ovo-like 1 (OVOL1). Nonetheless, the relation between FLG and OVOL1 is unclear. Because aryl hydrocarbon receptor (AHR; a ligand-activated transcription factor), plays a role in FLG expression in keratinocytes, we hypothesized that AHR regulates FLG expression via OVOL1. To demonstrate this mechanism, we analyzed FLG expression in OVOL1-overexpressing or OVOL1-knockdown normal human epidermal keratinocytes (NHEKs). Furthermore, we tested whether AHR activation by 6-formylindolo(3,2-b)carbazole (FICZ), an endogenous AHR ligand, or Glyteer, clinically used soybean tar, upregulates FLG and OVOL1 expression in NHEKs. We found that (1) OVOL1 regulates FLG expression; (2) AHR activation upregulates OVOL1; and (3) AHR activation upregulates FLG via OVOL1. Moreover, nuclear translocation of OVOL1 was less pronounced in AD skin compared with normal skin. IL-4-treated NHEKs, an in vitro AD skin model, also showed inhibition of the OVOL1 nuclear translocation, which was restored by FICZ and Glyteer. Thus, targeting the AHR-OVOL1-FLG axis may provide new therapeutics for AD.
丝聚蛋白(FLG)突变是特应性皮炎(AD)中一种已被充分证实的遗传异常。AD 的全基因组关联研究揭示了其他易感基因,例如卵清蛋白样 1(OVOL1)。然而,FLG 和 OVOL1 之间的关系尚不清楚。由于芳香烃受体(AHR;一种配体激活的转录因子)在角质形成细胞中FLG 的表达中起作用,我们假设 AHR 通过 OVOL1 调节 FLG 的表达。为了证明这一机制,我们分析了 OVOL1 过表达或 OVOL1 敲低的正常人表皮角质形成细胞(NHEK)中 FLG 的表达。此外,我们测试了内源性 AHR 配体 6-甲氧基吲哚并[3,2-b]咔唑(FICZ)或临床上使用的大豆油渣 Glyteer 激活 AHR 是否上调 NHEK 中的 FLG 和 OVOL1 表达。我们发现:(1)OVOL1 调节 FLG 表达;(2)AHR 激活上调 OVOL1;(3)AHR 激活通过 OVOL1 上调 FLG。此外,与正常皮肤相比,AD 皮肤中的 OVOL1 核易位不明显。体外 AD 皮肤模型 IL-4 处理的 NHEK 也显示 OVOL1 核易位受到抑制,而 FICZ 和 Glyteer 可恢复其核易位。因此,靶向 AHR-OVOL1-FLG 轴可能为 AD 提供新的治疗方法。